/channels/news_feeds/all/term/bioethics/rss en /channels/channels/news/stat-news-cancer-centers-sell-out-science-when-they-advertise-clinical-trials-treatment-286833 <div class="field field-name-body field-type-text-with-summary field-label-hidden"><div class="field-items"><div class="field-item even"><p> </p> <p>By Jonathan Kimmelman, associate professor at Ï㽶ÊÓƵ and director of its Biomedical Ethics Unit, and Alex John London (Carnegie Mellon) </p> <p>There is a lot of money behind providing cancer care, and cancer treatment centers spend an estimated $173 million on advertising each year. One of the ways they compete for patients is by offering a menu of clinical trial options and suggesting that participating in such trials gives patients an edge on their care.</p></div></div></div><div class="field field-name-field-published-date field-type-datestamp field-label-hidden"><div class="field-items"><div class="field-item even"><div class="custom-multi-date"><div class="multi-date first"><span class="label">Published: </span><span class="day">25 </span><span class="month">April </span><span class="year">2018</span></div></div></div></div></div> Wed, 25 Apr 2018 14:33:37 +0000 webfull 137576 at /channels /channels/news/expert-opioid-epidemic-260359 <div class="field field-name-body field-type-text-with-summary field-label-hidden"><div class="field-items"><div class="field-item even"><p>​<span>Prescriptions for dangerous alternatives to OxyContin are soaring, showing that a crackdown on the popular painkiller has failed to curb Canada’s opioid crisis.</span></p></div></div></div><div class="field field-name-field-published-date field-type-datestamp field-label-hidden"><div class="field-items"><div class="field-item even"><div class="custom-multi-date"><div class="multi-date first"><span class="label">Published: </span><span class="day">12 </span><span class="month">April </span><span class="year">2016</span></div></div></div></div></div> Tue, 12 Apr 2016 14:34:23 +0000 webfull 118135 at /channels